MNKD Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -40.84%, SMA50 -42.48%, SMA200 -34.2%). The stock’s 14-day RSI is 18.05 (weak momentum), while the ATR of 0.42 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -50.23% below its high and over -1.52% above its low. Average 10-day trading volume of 10.74 million shares is significantly above the 3-month average of 6.48 million, indicating heightened recent market interest.

MannKind Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.80. This means the shares are trading below this model’s fair value.

MannKind Corporation (NASDAQ:MNKD) closed at $3.52 USD, losing -$0.03 (-0.85%) from the previous close of $3.55. The stock is currently mid-range between its 52-week high and low $2.23 and $6.51. With a market capitalization of about $1.09 billion, MannKind Corporation is classified as a small-cap and shows market-like volatility (beta ~1.04). Key stats such as the average daily volume over the past year has been around 6.46 million shares, in line with its 52-week average. Headquartered in Danbury, CA, MannKind Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael E. Castagna, the company employs approximately 403 people and listed since July 28, 2004. MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.

MannKind Corporation has 306.83 million shares outstanding. The public float is 300.98 million shares, elevated short interest at 7.85% of float. This equals 23.75 million shares. The short ratio is 8.8 days. Institutional investors hold 56.8% of the float. Insiders own 1.66%. Castagna Michael holds 2.58 million shares, Tross Stuart A has 985.01 thousand shares and Thomson David has 841.72 thousand shares. Over the past six months, insider transactions show net selling. They sold 408.60 thousand shares across 6 transactions.

Wall Street analysts project EPS growth of 56.05% annually over the next five years. The latest quarter delivered EPS of -$0.05. The next quarter is forecast at $0.00. Next year's EPS is expected at $353.85. Analyst sentiment is bullish. Analyst rating data shows there are 13 Strong Buy ratings, 9 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $4.75. The high target offers 326.14% upside. The low target suggests 34.94% downside. The mean target is $9.20. This offers 161.36% upside. MannKind Corporation earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 06, 2026, missed forecasts by 150.0%. The prior quarter beat by 400.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in February 26, 2025.

MannKind Corporation trades at a P/E ratio of -45.31, slightly below the S&P 500 average, with a price-to-sales ratio of 3.01 and a price-to-book ratio of -18.3 indicating negative book value, which may reflect financial stress. The P/FCF stands at 83.55, also above market averages.

MannKind Corporation (NASDAQ:MNKD) shares are flat -3.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows MannKind Corporation trading at a premium to the broader market with a P/E of -45.31. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.28, suggesting 106.82% upside. Our AI forecast model points to short-term strength (4.83% over two weeks), a medium-term fall (-2.56% over three months), and a longer-term gain (28.98% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that MannKind Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.83%, with price expected at $3.69 by May 22, 2026, within a range of $3.49 to $3.88 3-Month Outlook: Projected fall of -2.56%, reaching $3.43 by August 06, 2026, with a range of $2.84 to $3.82. 1-Year Outlook: Projected gain of 28.98%, with price at $4.54 by May 07, 2027, within a range of $0.00 to $3.81.